<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00998699</url>
  </required_header>
  <id_info>
    <org_study_id>X052076</org_study_id>
    <nct_id>NCT00998699</nct_id>
  </id_info>
  <brief_title>Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well-controlled Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XOMA (US) LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>XOMA (US) LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that XOMA 052 may inhibit beta-cell destruction and enhance beta-cell
      regeneration.

      The purpose of this study is to assess the effects of XOMA 052 on beta-cell function and
      insulin production.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in beta-cell function as measured by change in C-peptide level during thd MMTT (Mixed meal tolerance test) at Day 112 compared to baseline (Day 0 pre-dose)</measure>
    <time_frame>Day 0 pre-dose and Day 112</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by pre- and post-treatment serial measurements of vital signs, clinical laboratory assessments, and treatment-emergent adverse events.</measure>
    <time_frame>Day 0 (baseline) through Day 364</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin requirements</measure>
    <time_frame>Day -3 through Day 0 pre-dose and Day 109 through Day 112)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c levels</measure>
    <time_frame>Day 0 pre-dose and Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucose</measure>
    <time_frame>Day 0 pre-dose and Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting glucagon and cortisol</measure>
    <time_frame>Day 0 pre-dose and Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systemic inflammation markers</measure>
    <time_frame>Day 0 pre-dose and Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in meal-stimulated GLP-1 and GIP</measure>
    <time_frame>Day 0 pre-dose and Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids profile</measure>
    <time_frame>Day 0 pre-dose and Day 112</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of serum concentrations of XOMA 052</measure>
    <time_frame>Day 0 pre-dose, Day 28, Day 56, Day 84, Day 112, Day 182, and Day 364</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>XOMA 052</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xoma 052</intervention_name>
    <description>Sterile solution subcutaneously administered every 4 weeks for 12 weeks</description>
    <arm_group_label>XOMA 052</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile solution subcutaneously administered every 4 weeks for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Stable Type 1 diabetes of &gt; 2 year duration

          -  No clinically significant change in treatment regimen for T1D

          -  Age ≥ 18 years and ≤ 55 years

          -  HbA1c &lt; 7.0%

          -  Positive GAD65 and/or IA-2 auto-antibodies

          -  Peak C-peptide &gt; 100 pM following IV injection of 1 mg glucagon

          -  Body-mass index (BMI) &gt; 18 and &lt; 28 kg/m2

          -  Willingness to maintain current doses/regimens of vitamins and dietary supplements
             through the end of the study

        Exclusion criteria:

          -  Current infection or history of infection

          -  Positive for Hep B surface antigen (HBsAg), Hep C virus (HCV), or HIV

          -  History of tuberculosis or positive PPD test

          -  Presence of foot, leg, or decubitus ulcers

          -  Current immunosuppressive treatment or documented immunodeficiency

          -  History of severe allergic or anaphylactic reactions

          -  History of asthma requiring systemic corticosteroid therapy

          -  Coronary intervention (PCI, stent placement) or hospitalization for cardiovascular
             condition within the last 12 months

          -  Uncontrolled hypertension

          -  History of congestive heart failure (NYHA Class III or IV)

          -  History of a coronary event within the last 12 months

          -  Female subjects who are pregnant, planning to become pregnant, have recently
             delivered, or are breast-feeding

          -  History of malignancy within the last 5 years

          -  Receipt of a live (attenuated) vaccine within the last 3 months

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc Donath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UniversitaetsSpital Zuerich</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2009</study_first_submitted>
  <study_first_submitted_qc>October 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2009</study_first_posted>
  <last_update_submitted>March 3, 2014</last_update_submitted>
  <last_update_submitted_qc>March 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Type 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

